Guardant Health, Inc. (NASDAQ:GH) Receives $39.67 Average PT from Analysts

Guardant Health, Inc. (NASDAQ:GH) has been given an average recommendation of “Moderate Buy” by the sixteen brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $39.67.

GH has been the topic of a number of research reports. Craig Hallum boosted their target price on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Citigroup boosted their target price on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen boosted their target price on shares of Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, Guggenheim raised shares of Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price target for the company in a research note on Friday, June 28th.

Guardant Health Stock Up 1.7 %

Shares of GH stock opened at $22.16 on Wednesday. The company has a market capitalization of $2.71 billion, a price-to-earnings ratio of -5.65 and a beta of 1.11. Guardant Health has a one year low of $15.81 and a one year high of $37.04. The company’s fifty day moving average price is $27.14 and its 200-day moving average price is $25.25. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The business’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Sell-side analysts expect that Guardant Health will post -3.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. increased its stake in Guardant Health by 10.5% during the 4th quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock valued at $353,000 after purchasing an additional 1,240 shares in the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Guardant Health by 8.5% in the 1st quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock valued at $382,000 after acquiring an additional 1,451 shares during the last quarter. Quarry LP purchased a new stake in shares of Guardant Health in the 2nd quarter valued at $44,000. Ensign Peak Advisors Inc boosted its holdings in shares of Guardant Health by 4.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 41,450 shares of the company’s stock valued at $1,197,000 after acquiring an additional 1,800 shares during the last quarter. Finally, Canton Hathaway LLC purchased a new stake in shares of Guardant Health in the 2nd quarter valued at $59,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.